CARLSBAD, Calif.--(BUSINESS WIRE)--Feb. 8, 2006--The Immune Response Corporation (OTCBB:IMNR) announced today that its management and the Board of Directors are implementing a new corporate and clinical strategy designed to position the Company for long-term success by more effectively leveraging its core immune-based technology for autoimmune and infectious diseases. Specifically, this strategy will focus on the accelerated development of the Company’s most promising immune-based therapies currently in clinical trials: NeuroVax(TM) for multiple sclerosis (MS) and IR103 for human immunodeficiency virus (HIV).
